Dr Jankowski presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from the ASPECT trial.

This was a phase III randomised trial in which Barrett’s oesophagus patients at a high risk of developing high-grade dysplasia or oesophageal cancer were treated with high dose proton pump inhibitors and aspirin, and Dr Jankowski estimates that this course of treatment prevented up to a quarter of cancers developing, and delayed its development by up to 2 years in other patients.

For more on these findings, watch his interview with ecancer, or read news coverage here.

View the slides here.